Vitamin D's hidden role in TB and fungal lung disease revealed
NCT ID NCT07516158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether vitamin D levels are linked to certain immune markers in people with active tuberculosis (TB), with or without a chronic fungal lung infection called aspergillosis. Researchers will compare blood samples from 300 adults—including healthy volunteers—to see how vitamin D relates to the body's immune response. The goal is to better understand these diseases, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2015
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants were recruited from specialized hospitals, including a national center for infectious diseases of Uzbekistan. The study population comprised patients receiving care for pulmonary tuberculosis, including those with coexisting chronic pulmonary aspergillosis, as well as healthy individuals from the local community.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * individuals with confirmed diagnosis of pulmonary tuberculosis * individuals with confirmed diagnosis of pulmonary tuberculosis and chronoc pulmonary aspergillosis * Healthy individuals Exclusion Criteria: * individuals \<18 years old; * those using immunosuppressants, antifungals and/or antibiotics within the three-month period prior to hospitalization; * patients with chronic or acute infectious diseases (excluding PTB and CPA) and non-infectious diseases; * subjects with difficulty collecting samples; and subjects unwilling or unable to provide written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic pulmonary aspergillosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Immunology of Fungal and Parasitic Diseases
Tashkent, Tashkent, 100151, Uzbekistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
- Two antifungal pills go head to head against a fungus that scars the lungs
- New drug RO7830698 put to the test for COPD
- Three pill versions of one drug go head to head in the bloodstream
- Pfizer tests RSV vaccine aimed at older adults
- Radioactive tracer maps where a new drug goes in the body